“Shkreli Award” goes to Moderna for “blatantly greedy” COVID vaccine prices

Abstract: Award judges cited Moderna’s pricing of its COVID-19 vaccine, which was developed with $1 billion in federal funding. Still, despite the tax-payer backing, Moderna set the estimated prices for its vaccine significantly higher than other vaccine developers. The Lown Institute’s judges wrote that, “given the upfront investment by the US government, we are essentially paying for the vaccine twice.”